Nov 172016
 

By Talent4Boards Team

Talent4Boards - Great Talent builds Great Boards

– USA, NY – Syntimmune, Inc., a clinical-stage biotechnology company advancing novel treatments for IgG-mediated autoimmune diseases based on leading expertise in FcRn biology, today announced the expansion of its leadership team and Board of Directors.… => Read more

Syntimmune appoints David De Graaf as CEO alongside Burt Adelman as new Board Member

From:: Syntimmune appoints David De Graaf as CEO alongside Burt Adelman as new Board Member

Sorry, the comment form is closed at this time.

%d bloggers like this: